Antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease

Date

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier BV

Abstract

No randomised clinical trials assessing the benefits and harms of antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease were identified. The benefits and harms of antifibrinolytic amino acids need to be tested in randomised clinical trials. Unless randomised clinical trials are conducted to assess the trade off between benefits and harms, we cannot recommend nor refute antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver diseases.

Description

Citaciones: 9

Citation